NCT01495065 - A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2011

Primary Completion Date

February 17, 2012

Study Completion Date

February 17, 2012

Conditions

Community-acquired Infection

Interventions

DRUG

GSK2251052 750 mg

Treatment A: 750 mg IV GSK2251052 single dose

DRUG

GSK2251052 1500 mg

Treatment B: 1500 mg IV GSK2251052 single dose

DRUG

GSK2251052 1500 mg BID

Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days

DRUG

GSK2251052 2250 mg

Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted

DRUG

GSK2251052 3000 mg

Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted

DRUG

GSK2251052 0.9% saline

Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted

Trial Locations (1)

91206

GSK Investigational Site, Glendale